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Objective: The purpose of this study was to evaluate the need for secondary interventions after endovascular abdominal
aortic aneurysm repair with current stent-grafts.
Methods: Studied were data from 2846 patients treated from December 1999 until December 2004. The data were
recorded from the EUROSTAR registry. The only patients studied were those with a follow-up of at least 12 months or
until they had a secondary intervention within the first 12 months. The cumulative incidences of secondary transabdom-
inal, extra-anatomic, and transfemoral interventions during follow-up (after the first postoperative month) were
investigated.
Results:A secondary intervention was performed in 247 patients (8.7%) at a mean of 12months after the initial procedure
within a follow-up period of a mean of 23  12 months. Of these, 57 (23%) transabdominal, 43 (16%) involved an
extra-anatomic bypass, and 147 (60%) were by transfemoral approach. The cumulative incidence of secondary interven-
tions was 6.0%, 8.7%, 12%, and 14% at 1, 2, 3, and 4 years, respectively. This corresponded with an annual rate of
secondary interventions of 4.6%, which was remarkably lower than in a previously published EUROSTAR study of
patients treated before 1999. Type I endoleaks (33% of procedures), migration (16%), and rupture (8.8%) were the most
frequent reasons for secondary transabdominal interventions. Graft limb thrombosis was the indication for extra-
anatomic bypass (60%). Type I endoleak (17%), type II endoleak (23%), device limb stenosis (14%), thrombosis (23%),
and device migration (14%) were themost frequent reasons for secondary transfemoral interventions. Operative mortality
was higher after secondary transabdominal interventions (12.3%, P  .007) compared with transfemoral interventions
(2.7%). Overall survival was lower in patients with secondary transabdominal (P  .016) and extra-anatomic interven-
tions (P < .0001) compared with patients without a secondary intervention.
Conclusion: Although the incidence of secondary interventions after endovascular aneurysm repair has substantially
decreased in recent years, continuing need for surveillance for device-related complications remains necessary. ( J Vasc
Surg 2006;43:896-902.)Endovascular treatment of abdominal aortic aneurysms
(AAA) has been used successfully for more than a decade. 1-3
Recently, two randomized trials demonstrated that aneurysm-
related mortality was lower in patients with endovascular
repair than in those with open repair of their aneurysm during
a follow-up period of 4 years.2,3 Despite this favorable mid-
term outcome, the long-term durability remains a subject of
concern, and life-long surveillance to observe satisfactory en-
dograft function is considered essential.4-8
Device-related complications such as endoleak and
graft migration were frequently observed. These events are
associated with an increased risk for aneurysm rupture and
therefore need to be identified as early as possible.9-10 Graft
From the EUROSTAR Data Registry Centre, Catharina Hospital, Eind-
hoven, The Netherlands.
This study was funded by EUROSTAR. None of the companies financing
EUROSTAR had any influence on study design, data collection and
analysis, interpretation, and writing.
Competition of interest: none.
Additional material for this article may be found online at www.jvascsurg.org.
Reprint requests: R. Hobo, Department of Surgery, Catharina Hospital,
PO box 1350, 5602 ZA Eindhoven, The Netherlands (e-mail:
eurostar@iae.nl).
CME article
0741-5214/$32.00
Copyright © 2006 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2006.01.010
896thrombosis may cause also considerable symptoms. These
adverse events are repaired by a secondary interven-
tion.4,11-13
The incidence of secondary interventions may be con-
sidered a surrogate parameter of impending failure of treat-
ment while also representing an important factor to main-
tain the long-term functionality of the stent-graft repair.
Secondary procedures can be categorized according to the
invasiveness of the procedure: (1) transabdominal interven-
tions (either with conversion to open repair or with preser-
vation of the endograft), (2) extra-anatomic interventions,
and (3) transfemoral interventions.
The need for secondary interventions after endovascu-
lar AAA repair had been investigated previously by using
the EUROSTAR database.4 In this previous assessment,
however, the study outcome was primarily determined by
the early generation stent-grafts. New developments in
endograft design most likely will provide better outcome
results.14 In the present EUROSTAR review, the need for
secondary interventions according to current treatment was
reassessed.
METHODS
Design. The project of European collaborators on
stent-graft techniques for AAA repair (EUROSTAR) reg-
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collating and investigating an extensive multicenter experi-
ence on endovascular AAA repair.15,16 Patients with a
nonruptured, asymptomatic infrarenal AAA who under-
went elective endovascular repair were prospectively en-
rolled into the registry after their consent and studied on an
intention-to-treat basis. All patients received commercially
available CE-approved stent-grafts. The endograft brands
that were used in this study included: Zenith (Cook,
Bloomington, Ind), Talent (Medtronic/AVE, Santa Rosa,
Calif, AneuRx (Medtronic/AVE), Excluder (W. L. Gore
and Assoc., Flagstaff, Ariz), Lifepath (Edwards Life-
sciences, Irvine, Calif), Fortron (Cordis/Johnson & John-
son, Ft Lauderdale, Fla) Powerlink (Endologix, Irvine,
Calif), Ancure (Guidant,Menlo Park, Calif), and Anaconda
(Sulzer Vascutech, Inchinnan, United Kingdom).
The EUROSTAR database is maintained on a Web site
(www.eurostar-online.org). This site offers data entry facil-
ities to participating physicians (KIKA Medical, Nancy,
France), and password-protected access is available for cen-
ters and companies to their own data. Alternatively, data
submission by fax or mail is available.
The current analysis includes 2846 patients from 131
centers (Appendix, online only). Primary procedures were
performed between December 1999 and December 2004.
The patients had a minimal follow-up of 12 months unless
a secondary intervention occurred before the 12-month
visit. These inclusion criteria were similar as in our earlier
series. Additional interventions performed at the time of
the initial procedure were not counted as secondary proce-
dures. Follow-up visits were scheduled at 1, 3, 6, 12, 18,
and 24 months postoperatively and annually thereafter.
The aneurysm diameter was determined over theminor axis
at the site of the largest cross section. All patients included
in the analysis had an aneurysm diameter of 40 mm.
The cumulative incidences of secondary interventions
were categorized in transabdominal, extra-anatomic, and
transfemoral procedures. In patients who underwent mul-
tiple procedures, only the most extensive procedure was
taken into account, and if two interventions of equal extent
were performed, the first one was considered the index
intervention.
Secondary interventions were correlated with findings
at computed tomography examination and clinical assess-
ment during follow-up to assess for reintervention. Indica-
tions included device migration, different types of en-
doleak, thrombosis, stenosis, kinking of endograft limbs,
and rupture of the aneurysm. In addition, procedure-
related mortality (defined as death30 days of the second-
ary intervention) and the all-cause mortality during
follow-up were compared among the three types of reinter-
ventions. Reporting was in accordance with the guidelines
of the ad hoc Committee for Standardized Reporting Prac-
tices in Vascular Surgery of The Society for Vascular Sur-
gery/American Association for Vascular Surgery.17
Statistical analysis. Kaplan-Meier life tables were
used to draw cumulative incidence and survival curves for
all types of secondary interventions. Values were repre-sented as means  standard deviation and ranges. Relative
risk ratios (RR) were calculated to correlate secondary
interventions with their indications in the follow-up visit
preceding reintervention. Multivariate logistic regression
was performed for independent comparisons of operative
30-day mortality. The multivariate Cox proportional haz-
ards model was used to calculate independent associations
with survival during the postoperative and entire follow-up
period. P  .05 was considered statistically significant.
Analysis was performed by using SAS (version 8.0) statisti-
cal software (SAS Institute Inc, Cary, NC).
RESULTS
The 2846 patients who constituted the study group
had a mean age of 72.0 7.5 years (range, 43 to 100 years)
at the time of the primary procedure. The Zenith endograft
was the most frequently used device (40%), followed by
Talent (28%) and Excluder (15%) (Table I). The mean
length of follow-up was 23  12 months (range, 1 to 60
months). During the follow-up period, the mean AAA
diameter shrunk from 58 to 51 mm. Most of the patients
were classified as American Society of Anesthesiologists
(ASA) grade II or III (Table II). In 1755 patients (62%),
the maximum transverse diameter of the aneurysm was
5.5 cm, and 1091 patients (38%) had an aneurysm be-
tween 4 and 5.5 cm.
Secondary interventions were performed in 247 pa-
tients (8.7%) at a mean time of 12 13months (range, 1 to
48 months) after the initial procedure. There was no sig-
nificant difference in the rates of reintervention between
the different stent-graft labels or bifurcated or aortouniiliac
endograft configuration. In large aneurysms (5.5 cm),
the incidence of secondary interventions after 2 years
(9.9%) was higher than in small aneurysms (9.9% compared
with 7.1%, Kaplan-Meier analysis P  .0348). No other
Table I. Endograft devices
Patients with secondary procedure (%)*
Zenith
†
91/1147 (7.9)
Talent
‡
77/791 (9.7)
Excluder
§
25/421 (5.9)
AneuRx
‡
29/264 (11.0)
Lifepath

12/67 (17.9)
Fortron
¶
2/52 (3.8)
Powerlink# 6/51 (11.8)
EVT** 1/36 (2.8)
Anaconda
††
4/17 (23.5)
*Percentage of endoprotheses of each device brand with secondary inter-
vention
†Cook Inc, Bloomington, Ind.
‡Medtronic Corp, Santa Rosa, Calif.
§W. L. Gore and Associates, Inc., Flagstaff, Ariz.
Edwards Lifesciences, Irvine, Calif.
¶Cordis/Johnson & Johnson, Fort Lauderdale, Fla.
#Endologix, Irvine, Calif.
**Guidant Inc, Menlo Park, Calif.
††Sulzer Vascutek Ltd., Inchinnan, United Kingdom.morphologic parameters were found to correlate with the
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out endoleaks (completely excluded), the incidence of sec-
ondary intervention after 2 years was lower than in patients
with endoleaks at the completion angiogram (8.2% com-
pared with 12.0%, P  .0133). Follow-up continued for a
mean of 11 12 months (range, 0 to 47 months) after the
secondary intervention.
A transabdominal approach was used for 57 of the
interventions (23%), 43 procedures (16%) involved extra-
anatomic exposure, and 147 interventions (60%) were
transfemoral procedures. The cumulative incidence of all
secondary interventions in the entire patient cohort was
6.0%, 8.7%, 12%, and 14% at 1, 2, 3, and 4 years respectively
(Fig 1). This corresponded with an annual rate of 4.6%.
Transabdominal secondary interventions. Conver-
sion to open AAA repair constituted 40 of the 57 secondary
transabdominal interventions. In 17, the endograft was
preserved, which involved a banding procedure for en-
doleak, iliofemoral bypass, or laparoscopic clipping. The
cumulative incidence of secondary transabdominal inter-
ventions was 0.9%, 1.9%, 3.2%, and 5.0% at 1, 2, 3, and 4
years, respectively.
The indications for conversion to open surgical repair
were rupture of the aneurysm in 5 (RR, 34.1), device
migration in 8 (RR, 24.2), type I endoleak in 10 (RR,
20.1), aneurysmal growth in 14 (RR, 14.6), and endograft
infection in 3 (RR, 71.2) (Table III). Eight patients had
more than one indication, and no indication was given in
five patients. The indications for secondary transabdominal
interventions with preservation of endograft function were
type I endoleak in five patients (RR, 28.3), thrombosis in
two (RR, 43.1), and aneurysmal growth in five (RR, 12.4).
Three patients had more than one indication, and no
indication was given in one patient.
Extra-anatomic secondary interventions. Most of
the extra-anatomic procedures (28 of 43) consisted of
femorofemoral crossover bypasses. In a few patients, axil-
lofemoral bypasses were used. The cumulative incidence of
Table II. Baseline characteristics
Characteristic All patients*
Patients with
secondary procedure*
Age at initial
procedure (yrs)
72.0 (43-100) 71.8 (48-89)
Gender
Males 2688 (94) 233 (94)
Females 158 (5.6) 14 (5.7)
Maximum AAA
diameter (mm)
58.3 (40-110) 60.0 (40-102)
ASA Physical status
I 249 (8.8) 21 (8.5)
II 1299 (46) 112 (45)
III 1127 (40) 101 (41)
IV 152 (5.4) 13 (5.3)
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesiol-
ogists.
*Values are represented as mean and range or as number and percentage.secondary extra-anatomic interventions was 1.2%, 1.6%,and 2.3% at 1, 2, and 4 years, respectively. The most
frequent indication for a secondary extra-anatomic bypass
graft was graft thrombosis in 24 cases (RR, 78.5) (Table
III). Further indications were type I endoleak in five (RR,
9.0) and stenosis in six patients (RR, 53.4). Two patients
had more than one indication, and no indication was given
in three patients.
Transfemoral secondary interventions. Secondary
transfemoral interventions consisted of 76 additional stent-
graft or stent placements, including endograft limb exten-
sions, stenting using bare stent or endovascular conversion
to an aortouniiliac endograft, 30 coil embolizations of
endoleak, 10 thrombectomies, and 13 angioplasty proce-
dures. In 18 patients, the type of secondary transfemoral
intervention was not specified. The cumulative incidence of
secondary transfemoral interventions was 3.7%, 5.4%, 6.8%,
and 8.0% at 1, 2, 3, and 4 years, respectively. All device-
related complications that were assessed during follow-up
correlated significantly with the use of secondary trans-
femoral interventions. Type I endoleak was present in 25
patients (RR, 9.5), type II endoleak in 34 (RR, 3.9), type
III endoleak in 12 (RR, 6.9), kinking in 9 (RR, 11.1),
stenosis in 20 (RR, 19.5), thrombosis in 23 (RR, 17.4),
device migration in 20 (RR, 10.9), aneurysmal growth in
15 (RR, 3.2), and rupture in 2 (RR, 4.7). More than one
indication was present in 22 patients. The indication for the
secondary intervention was unknown in 15 patients.
Risk factors for secondary intervention. Independent
baseline risk factors for secondary interventions were a
required adjuvant procedure (P  .0001), proximal en-
doleak (P  .0040), and midgraft endoleak (P  .0170)
evident at the primary procedure. Patient age, gender, ASA
risk classification, systemic comorbidities, type of device,
and preoperative aneurysm diameter with thresholds at 5.5,
6.0, and 6.5 cm were not independent risk factors for a
secondary intervention.
Secondary interventions and associated mortality.
The operative mortality rate after transabdominal reinter-
Fig 1. Freedom from secondary interventions.vention was 12.3%. This was significantly higher than the
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anatomic and 2.7% for transfemoral secondary interven-
tions (P  .0069). Six patients died after conversion to
open repair (15.0%), and one patient died after an
endograft-saving transabdominal intervention (5.9%). The
difference between these two was not significant (P .34).
Considering only conversions to open repair, operative
mortality was significantly higher than for less invasive
reinterventions, such as extra-anatomic and transfemoral
procedures combined (P .0009). The difference between
endograft-saving transabdominal intervention and the
combined group with extra-anatomic and transfemoral in-
terventions was not significant.
The all-cause mortality rate was higher for both sec-
ondary transabdominal interventions (P  .0157, hazard
ratio, 2.6; 95% confidence interval, 1.2 to 5.5) and extra-
anatomic interventions (P  .0001, hazard ratio, 2.0; 95%
confidence interval, 1.4 to 2.9) compared with patients
without a secondary intervention, independent of patient
age, fitness, endoleaks, and all graft-related complications,
as assessed by multivariate Cox regression. The 3-year
survival rates were 80.5%, 62.5%, and 86.2% for patients
with transabdominal, extra-anatomic, and transfemoral re-
interventions, respectively (Fig 2). All deaths after transab-
dominal reinterventions were operative death 30 days of
the secondary procedure; no further deaths occurred.
Seven patients who underwent extra-anatomic reinterven-
tions died of unrelated causes, and one died perioperatively.
The mortality rate for patients who underwent secondary
transfemoral interventions was not higher than for patients
without reinterventions. Ten patients who underwent
transfemoral reintervention died of unrelated causes, one
died of aneurysmal rupture, and three died of procedure-
related causes. The difference in mortality rate between
transabdominal and extra-anatomic reinterventions was
not significant (P  .33).
DISCUSSION
The main finding of the current study was a markedly
Table III. Indications for secondary interventions.
Indication Total* Conversion Other transa
Type I endoleak 144 14 5
Type II endoleak 370 7 6
Type III endoleak 101 4 2
Thrombosis 68 2 2
Stenosis 32 — 0
Migration 73 8 1
Kinking 40 1 —
AAA growth 43 14 5
AAA rupture 13 5 —
Bleeding/hematoma 8 2 1
Graft infection 3 3 —
Unknown — 5 1
AAA, Abdominal aortic aneurysm.
*Patients may have more than one indication.reduced annual rate of secondary interventions comparedwith the earlier EUROSTAR experience reported on the
patient series who had operations before December 1999
(4.6% vs 9.1%).4 In 8.7% of patients, a secondary procedure
was performed at some time during follow-up in contrast to
18% of patients in the early experience. A survey of 15
studies demonstrated secondary interventions in 17% of
patients (683/3905) with endovascular aneurysm repair,
ranging from 10% to 34%, which was higher than in the
current study.6,7,11-13,18-27 This is in agreement with our
present results and suggests that the need for secondary
interventions has tended to decline in recent years.
The lower rate of secondary interventions compared
with earlier implanted stent-grafts may be explained by
improved stent-graft design14 and by increased experi-
ence of the physicians.28 In grafts of early design, a
considerably higher secondary intervention rate of 48%
to 54% was reported.13,29 The main differences in base-
line variables between the two study periods included use
of current devices in 100% compared with 26% and a
median patient age of 72 vs 69 years in the present and
previous overview, respectively. Other variables, includ-
ing the median aneurysm diameter, were similar in both
studies.
There was a trend towards a higher relative propor-
tion of transabdominal and extra-anatomic reinterven-
tions compared with our earlier series (23% and 17% of
the total number of secondary procedures vs 12% and
11%, respectively). This trend was largely due to a signif-
icant decline in the need for secondary transfemoral
interventions compared with the earlier experience,
whereas the need for surgical procedures had not signif-
icantly decreased. However, the most frequently per-
formed reinterventions still consisted of transfemoral
procedures. In contrast with our findings, Flora et al13
reported a shift from open to endovascular secondary
interventions. In their experience, more complications
were managed by endovascular techniques over time
when they compared the outcome in two study periods.
In addition, a decreased incidence of device-related com-
inal Extra-anatomic Transfemoral No intervention
5 25 95
4 34 319
2 12 81
24 23 17
6 20 6
— 20 44
5 9 25
3 20 1
— 2 6
— 2 3
— — —
3 15 —bdomplications was observed in the more recent period, suggest-
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with by endovascular technique.
Similar to Sampram et al,12 proximal type I endoleak
evident on the completion angiogram was predictive of
later secondary interventions. They found that the inci-
dence of secondary interventions correlated with the
aneurysms with the largest diameter and whether the
patient was treated later in the study period. The given
explanation was that reinterventions were performed
more aggressively in large aneurysms and increased over
time with more anatomically challenging cases. We could
not confirm the aneurysm size, and we found an opposite
association for the frequency of reinterventions over
time. This was in agreement with their expectation that
newer devices might diminish the rate of secondary
procedures.
Transabdominal and extra-anatomic procedures were
more risky for the patient, as these procedures generally
were associated with a higher mortality rate. Extra-
anatomic procedures had an increased risk of late death
independent of patient fitness and prothrombotic state, and
transabdominal procedures were associated with increased
operative mortality. The mortality rate of 15% after second-
ary conversion to open repair was high and exceeded the
perioperative mortality rate after elective open repair.30,31
This observation was in agreement with the findings in
other studies ranging from 0% to 40%11,12,18,21,22,26,32-34
but is lower than the reported 24.4% mortality after sec-
ondary conversion in the earlier EUROSTAR experience.9
When a transabdominal reintervention was survived for the
first month, no further deaths during continued follow-up
were recorded in the present study cohort. This suggests
that patients who were medically fit were selected for an
open secondary intervention.
From the previous EUROSTAR and other studies, a
considerable amount of device-related complications are
known to occur for which no reinterventions are per-
formed.16,19 Some of these will be managed conserva-
Fig 2. Survival.tively, and there is a consensus that type II endoleakswithout aneurysm growth should be treated expecta-
tively.35 Other endoleaks and graft complications may
intentionally be left untreated because the patient is
unfit. Most physicians will agree, however, that a second-
ary intervention is definitely indicated in case of aneu-
rysm growth, whereas the complication may only be
observed in shrinking aneurysms.
Some patients in the EUROSTAR cohort were await-
ing intervention that had been planned, but was not yet
performed, and some reinterventions may have yet to be
reported because of delay in follow-up data entry. This may
underestimate the incidence of secondary interventions.
On the other hand, some secondary interventions were
performed without a recorded indication (ie, missing infor-
mation). This under-reporting of indications is a weakness
of a voluntary registry such as EUROSTAR. Elaborate case
record forms may cause poor compliance of participants,
and the follow-up form that was used represented an un-
avoidable compromise.
Further limitations included possibly a lack of consec-
utive patient entry. Because patient enrolment was volun-
tary, it was not known how many centers did not enroll all
of their patients but only selected cases. From personal
communication with participating centers, we suppose that
most did enroll consecutive cases, at least for the period of
participation in the registry. An additional aspect that may
have influenced the observed rate of secondary interven-
tions was the exclusion from our analysis of patients that
had an uneventful follow-up period of1 year. The reasons
for this were:
1. The requirement of a secondary intervention is a
function of follow-up time. Including many patients
with short follow-up would have resulted in a relative
lower rate, whereas we wanted to avoid a picture that
was too positive regarding the need of secondary
interventions.
2. A comparison of the rates of performed reinterventions
with the outcomes in our previous publication4 was
considered most important. That substantially lower
secondary intervention rates were found indicates the
positive effect of the use of current generation stent
grafts.
Accurate parameters that define the need for secondary
interventions to treat endoleaks have not yet been fully
established.13 Expansion of the aneurysm sac is, however,
an accepted indication for reintervention.36 In the present
study, aneurysm expansion was observed in 17% of patients
with secondary interventions, and it was the only reason in
10%.
CONCLUSION
The incidence of secondary interventions after en-
dovascular aneurysm repair had decreased significantly
in recent years. This decrease was mostly due to a lower
incidence of transfemoral secondary procedures. Trans-
abdominal and extra-anatomic reinterventions had rel-
atively decreased less and were associated with an
JOURNAL OF VASCULAR SURGERY
Volume 43, Number 5 Hobo and Buth 901increased mortality risk. Continuing need for surveil-
lance with regard to device-related complications re-
mains necessary.
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